Open label safety evaluation of specific immunotherapy in subjects aged 5-17 years suffering from seasonal rhinoconjunctivitis due to grass pollen not responding to pharmacotherapy
Latest Information Update: 05 May 2006
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Adverse reactions
- 05 May 2006 New trial record.